A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGF-receptor 2, in patients with advanced pancreatic cancer.

Friedrich Hubertus Schmitz-Winnenthal,Lilli Podola,Nicolas Hohmann,Tobias Friedrich,Heinz Lubenau,Marco Springer,Klaus M. Breiner,Gerd Mikus,Markus W. Büchler,Anne-Valerie Keller,Ruhan Koc,Christoph Springfeld,Phillip Knebel,Thomas Schmidt,Mariana Bucur,Lars Grenacher,Walter E. Haefeli,Philipp Beckhove

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGF-receptor 2, in patients with advanced pancreatic cancer.

2016

Friedrich Hubertus Schmitz-Winnenthal
Lilli Podola
Nicolas Hohmann
Tobias Friedrich
Heinz Lubenau
Marco Springer
Klaus M. Breiner
Gerd Mikus
Markus W. Büchler
Anne-Valerie Keller
Ruhan Koc
Christoph Springfeld
Phillip Knebel
Thomas Schmidt
Mariana Bucur
Lars Grenacher
Walter E. Haefeli
Philipp Beckhove

3091Background: VXM01 is an orally applied tumor vaccine based on live, attenuated salmonella bacteria carrying a eukaryotic expression plasmid, which encodes VEGFR-2. A recent randomized and place...

Keywords:

Cancer research
Pancreatic cancer
T-cell vaccine
VEGF receptors
Vaccination
Pathology
Medicine
Immunology
Salmonella bacteria
prokaryotic expression
vegf receptor 2
in patient
Plasmid
prime boost vaccination

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations